GV20 Therapeutics
Kelly Heaphy is a skilled research professional currently serving as a Research Associate II at GV20 Therapeutics since October 2023. Prior to this role, Kelly worked as an Associate Scientist I in Oncology Research at 2seventy bio, focusing on IND-enabling studies for the MUC16 program targeting ovarian cancer. Kelly's experience also includes working as a Research Associate at Bio-Techne, where the role involved cultivating T cells and optimizing a T cell activation platform. Earlier positions include supervisory and cashier roles at Robert Moses State Park, where oversight of toll collection and daily cash management occurred, along with experience as a gymnastics camp counselor teaching children. Kelly holds a Bachelor's degree in Bioengineering from Lehigh University, completed in 2022.
GV20 Therapeutics
1 followers
GV20 Therapeutics is the US branch of GV20 Oncotherapy. The company utilizes high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets, and discover and develop effective antibody drugs in cancer. GV20's proprietary antibody drug discovery engine has helped establish a solid portfolio of immuno-oncology antibody drug candidates for cancer treatment.